Advertisement

RareCyte signs CRADA with NCI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RARECYTE Inc. signed a Cooperative Research and Development Agreement with NCI for a three-year collaboration to investigate the use of RareCyte’s technology to identify, characterize, capture and analyze rare immune cell populations as well as individual circulating tumor cells derived from preclinical and clinical studies conducted by the NCI. The specific goals of the CRADA...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

The day before health economist Jay Bhattacharya stepped into his new role as NIH director, he sent a document to his employees outlining his top five priorities for the department, which included “reproducibility” and “transparency,” two themes he discussed at his confirmation hearings (The Cancer Letter, March 7, 2025).
Advertisement
Advertisement